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FK 506 Versus Cyclosporine in Pediatric Liver Transplantation 
A.G. Tzakis. J. Reyes. S. Todo. M. Green. T. Ohya. A. Jain. K. Abu-Elmagd, M. Alessianl. J.J. Fung, ar1 
T.E. Slarzt 
No GROUP of pauents IS likely to benefit more by improvements in Immunosuppression than the pedi-
atnc transplant recIpients who face life-long treatment. 
The advent of cyclosponne teyA) has transformed liver 
transplantation into the preferred treatment modality for 
chronic liver failure. I Its effect on pediatric liver transplan-
tation was profound. allowing for acceptable patient and 
graft survival when used with steroids at a fraction of the 
dose necessary under previous ImmunosuppressIve regi-
mensK;~ Complications Included renal toxIcity. hypenen-
sian. gum hyperplasia. hirsutism. and an uncommon but 
very troubling syndrome at' facial disfigurement. 
FK 506. a new ImmunosuppreSSIve agent denved from 
Streptomyces tsukubaenSIS. was nrst shown !O be erika-
claus In exoenmental) and clinical pnmarv liver transplan-
tation. aJ-12 :lOd also In reversing rejection In patients who 
failed CyA treatment. lJ 
Additional indications for use In pediatrics were its 
apparent simplicity oi use. low toxicity. and independence 
from adjuvant steroId therapyKDg-f~ 
This report summanzes our clinical experience with FK 
506 from a prospective study of children who underwent 
pnmary liver transplantation at the Children's Hospital of 
Pittsburgh between October 1989 and October 1990. Fol-
low-up is provided up to April 1991. 
METHODS 
Patient Selection 
BeginnlnSZ In October 1~l!9K children underszolng first·tlme liver 
! r.lJ1Splantatlon at the Children s Hosoltal of Pittsburgh were 
dllZlble to partiCIpate In a prospeCUYe Clinical evaluauon 01 the 
new Immunosuppressant. FK 506. Infonned consent was ob-
tamed from the parents 01 all eligible children pretransplant. There 
were no exclUSIons. Histoncal controls who recelYed eyA and 
matched on age (within 6 months •. pnmary diagnOSIS. and UNOS 
~eventv score were Idenuried for eaCh patient as soon as poSSIble 
posttnulsplant. Eligible controls were children who had under-
gone pnmarv liver trans!'iantauon at our center between January 
1988. after which time the UmversltY 01 WisconSin solution was 
lIsed for ornn preservation In all pedJatnC cases. and Oclober 
1989. A Single control was randomly selected from aU (n - I to 12) 
,0nlrOls matched for each pauent. It was poSSible to match 50 
~ontrols to :;9 studv patlenls. 
Data Collection 
The charts 01 both paUents and controls were systemaucallv 
reVlewe<l ullhzmr( slandan1Jzed datasheets and detlnltlons bv a 
'Ingle data collector. and revlewe<l bv a Single Invesugator. 
Inoauent and outpatient charts were reviewed. Datapolnts In· 
.:lucied paUent SUrvIval. durauon OllnlenSIVe care and hosplW 
,[avo days 01 feyer. results olliYer bIopsIes. liver function tests as 
measureG blocnerrucaily and bv syntneuc luncuon. renal function 
as measured by BUN and creatlmne. hematology, use of immu-
nosuppressants. antimicrobial. and antlhypenenslve agents. 
IMMUNOSUPPRESSION 
Study Group 
FK 506 was given as a continuous infusion of 0.15 mgtlcg 
per day. immediately after transplantation. and convened 
to 0.3 mg/kg per day in two divided doses postopenltlvelv 
when ora! diet was tolerated. Prednisone or prednisolon~ 
were given at doses of 20 mgtd for children> 10 kg body 
weight and 10 mg/d for children < 10 kg body weIght. 
respectively. and was reduced gradually after I week 
postoperatlvelv. being discontinued before dischanzz 
rejection-free state was achieved. 
FK 506 serum levels were momtored once or t\\lce 
weekly. There was no attempt to modify the dose of the 
drug in order to achieve a cenaln level. 
Control Group 
ImmunosuppressIon was given as previously descnbed. J 
Briefly. I V Cy A was given (6 mgtlc:g per day in two diyided 
doses over 4 hours each' immediately after surgery. Oral 
CyA (17.5 mg/lc:g per day) was given when oral feedings 
were well tolerated. The IV CyA was discontlnued when 
whole blood CyA levels of approXimately 1000 ngtmL 
could be maintained on ora! Cy A alone. 
Prednisone was given after repert'usion of the grau as a 
bolus of I g of hydroconasone tor smaller children. or I~ 
prednisolone for children larller than 20 kg body Wc' 
Subsequentlv. a steroId taper over j days. starong at .J\l 
mg/d for larger children or 100 mg/d for smaller chaldrcn 
was given. The maintenance dose was 20 mgtd initially. 
and then gradually tapered to the lowest dose necessary to 
mamtain a rejection-free state. 
TREATMENT OF REJECTION 
Study Group 
RejeCtion was treated by augmentauon of the FK 506 or 
prednisone dose. steroid bolus. recycle. or OKTI as 
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clinicaily mdicated. The dose of FK 506 was not aug-
mented if there was Significant Impaument of renal func-
tion. 
dose was augmented if whole blood levels were less 
WOO ngtmL. The prednisone schemes used for induc-
tion were repeated if necessary. OKTJ was used in steroid-
resistant rejections. Azathiopnne was added to the reg!-
if needed to mamt.aJn a rejection-free state. 
clinical course of these 109 patients was reviewed. 
The baseline clinical profile of the pauents in the two 
groups and technlcal complications were SImilar 1 Tables I 
and 1). 
~Aqfbkq AND GRAFT SURVIVAL 
At the end of follow-up (April 1991). 53 (90%) pauents are 
alive In the FK 506 group vs 38 (76%) in the CyA group. 
Table a.. Technical COIftl)lIcmlons ~ 
Con1DICIDOna F1( !!OIl CyA 
POSIDpwaave bIeeOIng 8 4, 
~ IIttIlfY tnromDOSlS 6 8" 
Par1II/ vetn mromtlOSlS 0 2 
Cava ItllamtlOSlS amaure 0 0 
Rupture 01 DSlIUOOIII1Ulm of PV 0 1 
BlIarv stnctunt 4 5 
RIII8ntJon 01 stant 1 , 
BIIIrv 1881U1Qe 1 f 0 
D~Dnag aDscess 2' 0 
Bowel oertorabOl'l 0 
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fig 1. Actuarial patient sUMVal in pediatnc liver Tx. 
Actuarial survival. as shown in Fig I. was always better in 
the FK 506 group: 92% vs ISO% at 3 months. 90% vs 78% at 
6 months. 90 vs 78% at I year. and 90 vs 76% at 18 months 
for each group. respectively (P = .11). 
Actuarial graft survival. as shown in Fig 2 is 85% vs 70% 
at l months. 83% vs 68% at 6 months. 83% vs 68% at I 
year. and 83% vs 66% at 18 months. again for each grouP. 
respectively (P = .12). 
Overall. 7 pataents (12%) required a second graft in the 
FK 506 group vs 9 (18%) in the CyA group (P = NS), One 
Cy A patient required a third graft. An account of the 
causes of mortality and retransplantation is presented in 
Tables 3 and 4. 
Adjuvant CorticosteroId Therapy 
There are significant differences In both the percentage 
lreated and median dose received (Figs 3 and 41. Pred-
nisone was used by all Cy A pauents throughout the study 
penod. except one patient who was successfullv WIth· 
drawn at 'J months aiter transplantauon. In contrast. 
prednisone use In the FK group dropped rapidly to 17% at 
3 months. 12% at () months. to just under 10% beyond 9 
months (P =001). The inducuon of predrusone was 
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Table 3. Cau.. of DuttI Attar Tran..,...uon 
F alai II'Ilectl0n5 
Openmve 
Tumor recurrence 
Portal vem mrombOsis 
Rejecbon 
PrimlllY nontuncbon 
I ntracerecraJ hemOrrtIag& 
Tolal 
2 
2 
6 
CvA 
7 
2 
12 
significantly less in the FK group (see METHODS). The 
few patients still on prednisone In the FK group received a 
smaller dose than the eyA pauents. 
Adjuvant Azathlopnne Therapy 
:-.l'one ot the FK S06 patients received malOtenance authl-
llpnne. Azathiopnne was used in about 55% of the CyA 
patients as adjuvant mamtenance ImmunosuppressIon. 
Drug Levels 
CyA levels were highest at I week (median 1022 nglmL). 
Maintenance levels beyond 6 months were approxlmatelv 
400 ngJmL. FK S06 levels were highest at I day (median 
1.65 ngtmLl. and were maintained after 6 months at levels 
below O.S ngJmL. 
HematologiC and BiochemICal Profile 
The hematologic and biochemical pronles were Similar in 
both groups (Figs 6 and 7) except for serum B UN which 
showed a trend favonng FK 506 after 0 months (p = !'IS), 
COMPlICA TIONS OF IMMUNOSUPPRESSION 
Rejection 
Overall. 45 176%) of the studv patients and 3S (70%) of the 
control patients expenenced at least one rejection during 
follow-up. There was no difference between groups 10 the 
inCidence of mUltiple reJections. as 32% in each group 
C!xpenenced two or more episodes of rejection. 
The seventy of rejections. Judged by the treatment 
required. was noticeably different between groups. Of the 
78 episodes oi rejectton treated in the FK S06 grouP. onlv 
I (1%) reqUired retransplanratton. to (13%) OKT3. 7 (9%) 
qabSe~K Cauaee of Retra,...nt8ttOn In the Study VeniUS 
ConInII Group 
Fl( 508 CyA 
HeoabC anerv mromDOSls 2 3 
Primarv nonruncaon 3 2 
RejecDon 2 3 
AdenlMrus neoaus 
Total 7 9 
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FIg 3. Percentage of paliants on adjUVant sterotd th8l'8lJV. 
steroid recycle. 53 (68%) a single steroid bolus. 57 (73%) 
augmentatton of the baseline FK dose. and 41 (53%) 
augmentatton of the baseline sterOid dose. The 55 epIsO<les 
n! rejection In the CvA group reqUired 2 (4%) ret:7'. 
plants. 18 03%) OKT3. 22 (40%) a sterOId recvcl!;. J 
(71%) a sterOId bolus. 27 (49%) augmentatlon ofCyA dose. 
and 26 (47%) augmentation of the baseline steroid dose. 
OKT3 was used 2.S·fold (P =01) and steroid recycle 
4.4 fold (P < .000)) more frequently in the eyA group. In 
contrast. increased FK 506 dosage was I.S-fold more 
frequent than increased eyA dosage tP < .01). 
Infections 
The infectious complications occurring during the first 90 
days after liver transplantatton In children treated with FK 
S06 and their historical controls are outlined in Table 5. 
The mean number of infectious episodes was significant Iv 
Ic!ss in patients treated with FK 506 compared to controls 
{ 1.4 vs 2.0. P = .041. The type and frequency of infectlc 
were slmtiar m the two groups. with the exception In:. 
catheter-associated mfectlon was seen much more Ire· 
Lluently in the histoncal group. After exclusion of catheter· 
aSSOCiated bacteremia. the mean number 01 infectious 
episodes per pattent seen 10 pattents receiving FK S06 was 
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:-: still less than that of controls. though the difference was no 
fo. longer significant 11.25 ys 1.54. P = NS). 
~ CMV was the most common virai pathogen seen m both 
!- groups of patients. Primary CMV infection occurred in 7 of 
:.. 14 epIsodes m patients on FK 506 compared to 5 of 13 
1-\ episodes in patients in the historical control group. Inva· 
;... sive CMY disease. consisting of ententis. hepautis. or £. pneumonta. was seen in II of 14 episodes in patients 
~~ treated with FK 506 compared to 8 of I J episodes in 
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100"" 
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r_ .... u. study vs control group. 
control patients IP = NS). Hepatitis was the most common 
invasive site in both groups. 
A trend toward an increase in fata! infections was seen in 
control patients (2 of 59 vs 7 of 50. P < .08l. Pathogens 
associated with a singie episode of fatal infection in pa-
tients treated with FK 506 included CMY and Asper~iifus 
!llmi,alus. Pathogens associated with a smgie episode of 
fata! infection in the control group mcluded CMY. adeno-
virus. CMY and adenOVIrus. inftuenza A. and Slaphvio-
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Fig 7. InCIdence of hypenenslon requumg treaonent In Study vs 
comrot group. 
coccus aurl!us: Entl!robaclI!r cloacal! was the pathogen m 
two fatal infections. 
l ympnoorouferatJve Disease 
Lympnoprohferatlve disease was diagnosed in three pa-
tients In the FK group and two In the CyA group. none of 
[hem were fatal or requtred retransplantatlon. They were 
all treated with reduction of the immunosuppressIOn and 
IV acyclovir. One patient in the study group underwent a 
right hemIcolectomy ior intestinal Iymphoproliferatlve dis-
ease. 
Hypertension 
Hypenension was seen less often as judged by the use of 
antihypenenslve treatment. Diltiazem was not conSidered 
as an antihypenensive in the Cy A group because It was 
frequently given to increase CyA blood levels. 
Antihypenensives were gaven to 17% of the patients at I 
Table 6.lnt.c:uoua Co"",,1C8tIOna Dunng the FI .... to Days Attar 
Pedtatrtc Uver qfDff~: FK SOl VlraUi Contro •• 
FI( !508 ConIroI 
T olal eplsooas mtecllon 82 loa-
Epiaoael/08lMlntll 1.4 2.0' 
F alai tntecbOnS 2 7 
Bactenal IntecbonS 42 60 
Fatal 0 3 
Baderem18 13 35 
lKgneKelsoaa~ 5 22 
Other IOUrat identified 3 9 
Intra'aDOOmInaI wIthOUt baCleremta 7 6 
Wouna 4 1 
Other 18 19 
Virallnt8CllOnS 3J 32 
Fat" 4 
CMV 14 13 
AdenovIrus 4 7 
Other 15 12 
FUngal 8 10 
Fatal 0 
. p. 04 Oy SlucMfW'I r _1Or ...... ......-· 
'P <: OSOyFIlhlrIEuct r ... 
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day after transplantation. and decreased gradually to 8% at 
15 months in the FK group. In the CyA group. the use of 
antlhypenenslves was significantly higher at I day \65%), 
and remamed elevated at all time pomts (45% at I ~ 
monthsl (P = .01 I. 
DISCUSSION 
The decision to proceed with this prospective trial for the 
evaluation of FK 506 in primary pediatric liver transplan-
tation was made with a majority vote of the Institutional 
Review Board of the Children's Hospital of Pittsburgh. 
The study takes advantage of a large inventory of histoncal 
controls in our program. operated upon and cared for by 
the same team using the same preservation and SUrgical 
techniques as in the study group. The controls were 
matched for age. disease. and medical urgency at the time 
of transplantation. It was pOSSible to Identify such controls 
for the maJonty of the study patients. 
Companson oi patient and grait survival between the 
two groups favors the FK 506 group, a difference whlcn 
did not achieve statlstlcaJ significance. due to the mOOest 
~ample size. 
Although the number of rejection episodes was similar 
in the two groups, rejections were easier to manage in the 
'itudy group. Infections were less common and Jess severe 
in the study group. Similarly. hypenension was signifi-
candy less common in the study group. 
There was a lower requirement for chronic steroid use. 
with less than 10% of the study patients requiring chromc 
steroids. versus an almost universal requirement in the 
control group. Adjuvant azathiopnne was only needed in 
the control group. 
Evaluation of hirsutism or facial disfigurement were not 
included in the study because these side effects are difficult 
to quantitate. panlculartv In the control group. Hirsutism 
or facial disfigurement have not been seen In the studv 
group. 
The internal milieu was Identical in both groups ot 
patients. at least as judged by blood chemistry and hema-
lology examinations throughout the study penod. A sale 
exception was a decreased serum BUN in the study group 
starting at b months after transplantation. which was not 
statistically significant. 
In conclusion. FK 506 compares favorably to CyA for 
use in pnmary liver transplantation. There IS a persistent 
trend for Improved patient and grait survival with less 
frequent anllhypenenslve treatment and vinual elimina-
!Jon of adjuvant steroid therapy, 
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